目的探讨肝动脉化疗栓塞(TACE)加门静脉化疗治疗原发性肝癌的效果。方法将54例原发性肝癌患者采用seldinger法穿刺插管超选择到肿瘤血供部位,在靶血管注入药物及栓塞剂(化疗药物:5-Fu 0.75～1.0,DDP 80～100mg,ADM 40～50mg或HCPT 20～30mg,栓塞剂为超液化碘油和明胶海绵)三天后患者在B超引导下进行经皮门静脉穿刺置管,注入化疗药物,剂量为TACE的1/3,其中5-Fu泵入。三周或四周后行第二周期治疗,四周后行疗效评价。结果CR4例(3.7%),PR22例(40.7%)。NC 25例(46.3%)。PD3例(5.6%)。CR+PR 26例(48.2%)。一年生存40例(74.1%),二年生存24例(44.4%),三年生存16例(29.6%)。门脉瘤栓完全消失4例,3例缩小。治疗过程中,未发现新的肿瘤病灶。结论肝动脉、门静脉双介入化疗联合治疗肝癌,安全有效,生活质量提高,生存时间延长,值得推广应用。 Objective To investigate the effect of transcatheter arterial chemoembolization (TACE) combined with portal vein chemotherapy in the treatment of primary liver cancer. Methods Fifty-four patients with primary hepatocellular carcinoma (HCC) were selected by seldinger puncture intubation for the tumor blood supply site. Drugs and embolic agents were injected into the target vessel (chemotherapeutic drugs: 5-Fu 0.75-1.0, DDP 80-100 mg, 50mg or HCPT 20 ~ 30mg, embolization of liquefied lipiodol and gelatin sponge) three days after the patient underwent B-guided percutaneous portal vein puncture catheterization of chemotherapy drugs, the dose of TACE 1/3, of which 5-Fu Pump in. Three weeks or four weeks after the second cycle of treatment, four weeks after the curative effect evaluation. Results CR4 cases (3.7%), PR22 cases (40.7%). NC 25 cases (46.3%). PD3 cases (5.6%). CR + PR 26 cases (48.2%). Forty cases (74.1%) survived a year, 24 cases (44.4%) survived two years and 16 cases (29.6%) survived three years. Porta tumor thrombus completely disappeared in 4 cases, 3 cases reduced. During treatment, no new tumor lesions were found. Conclusions Both hepatic artery and portal vein chemotherapy combined with hepatocarcinoma are safe and effective, the quality of life is improved, and the survival time is prolonged. It is worth popularizing and applying.